Form 4: David Portnoy, Chairman and Co-CEO of Cryo Cell International, Reports Changes in Beneficial Ownership
SEC Form 4
David Portnoy, Chairman and Co-CEO of Cryo Cell International, files a Form 4 detailing changes in beneficial ownership, including the acquisition of new stock options.
Summary
- David Portnoy, Chairman and Co-CEO of Cryo Cell International Inc. (CCEL), filed a Form 4 with the SEC.
- The filing reports changes in Mr. Portnoy's beneficial ownership of the company's securities.
- The reported transactions include the acquisition of 50,000 stock options with an exercise price of $8.08, vesting in three tranches on January 21, 2025, January 21, 2026, and January 21, 2027, and expiring on January 21, 2030.
- Mr. Portnoy directly owns 804,742 shares of common stock.
- He also indirectly owns shares through various entities including a 401K (117,012 shares), IRA (230,621 shares), spouse (102,586 shares), Mayim Limited Partnership (152,882 shares), uTIPu, Inc. (55,219 shares) and as custodian for his children (38,246 shares).
- Mr. Portnoy also directly owns stock options for 459,879 shares of common stock at various exercise prices and expiration dates.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing indicating insider activity, which can be interpreted as either positive (confidence) or potentially negative (insider selling), but without additional context, it's difficult to assess definitively.
Positives
- The acquisition of new stock options by the Chairman and Co-CEO could be interpreted as a sign of confidence in the company's future performance.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. Investors often monitor these filings to gauge management's sentiment and confidence in the company's prospects.
Stakeholder Impact
- The filing provides transparency to shareholders regarding the ownership stake of a key executive.
Key Dates
| Date | Description |
|---|---|
| 08/30/2019 | Date of stock options with an exercise price of $7.53, expiring on 08/30/2029 |
| 12/20/2019 | Date of stock options with an exercise price of $7.28, expiring on 12/20/2029 |
| 12/22/2021 | Date of stock options with an exercise price of $12.27, expiring on 12/22/2028 |
| 12/23/2022 | Date of stock options with an exercise price of $4.3, expiring on 12/23/2027 |
| 01/03/2023 | Date of stock options with an exercise price of $4.77, expiring on 01/03/2028 |
| 12/22/2023 | Date of stock options with an exercise price of $6.47, expiring on 12/22/2028 |
| 01/21/2025 | Date of the reported transaction and grant date of new stock options with an exercise price of $8.08, expiring on 01/21/2030 |
| 01/23/2025 | Date of signature of the reporting person |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.